Login / Signup

Case Study Cites Immune Reaction to High Adeno-Associated Virus Dose in Explaining Duchenne Muscular Dystrophy Trial Death.

Alex Philippidis
Published in: Human gene therapy (2023)
Keyphrases
  • duchenne muscular dystrophy
  • study protocol
  • phase iii
  • clinical trial
  • phase ii
  • muscular dystrophy
  • gene therapy
  • randomized controlled trial
  • open label
  • double blind